S&P 500   4,267.21 (-0.88%)
DOW   33,931.85 (-0.64%)
QQQ   328.60 (-1.11%)
AAPL   173.88 (+0.49%)
MSFT   291.65 (-0.36%)
META   175.90 (-1.99%)
GOOGL   120.36 (-1.10%)
AMZN   141.91 (-1.98%)
TSLA   906.57 (-1.43%)
NVDA   183.44 (-2.83%)
NIO   20.40 (-2.44%)
BABA   91.17 (-1.60%)
AMD   97.61 (-2.58%)
MU   61.33 (-3.96%)
T   18.42 (-0.81%)
CGC   4.23 (+11.90%)
F   16.17 (-1.58%)
GE   79.98 (-1.34%)
DIS   123.86 (-0.88%)
AMC   23.67 (-4.59%)
PYPL   100.19 (-1.85%)
PFE   49.50 (-0.72%)
NFLX   240.70 (-2.03%)
S&P 500   4,267.21 (-0.88%)
DOW   33,931.85 (-0.64%)
QQQ   328.60 (-1.11%)
AAPL   173.88 (+0.49%)
MSFT   291.65 (-0.36%)
META   175.90 (-1.99%)
GOOGL   120.36 (-1.10%)
AMZN   141.91 (-1.98%)
TSLA   906.57 (-1.43%)
NVDA   183.44 (-2.83%)
NIO   20.40 (-2.44%)
BABA   91.17 (-1.60%)
AMD   97.61 (-2.58%)
MU   61.33 (-3.96%)
T   18.42 (-0.81%)
CGC   4.23 (+11.90%)
F   16.17 (-1.58%)
GE   79.98 (-1.34%)
DIS   123.86 (-0.88%)
AMC   23.67 (-4.59%)
PYPL   100.19 (-1.85%)
PFE   49.50 (-0.72%)
NFLX   240.70 (-2.03%)
S&P 500   4,267.21 (-0.88%)
DOW   33,931.85 (-0.64%)
QQQ   328.60 (-1.11%)
AAPL   173.88 (+0.49%)
MSFT   291.65 (-0.36%)
META   175.90 (-1.99%)
GOOGL   120.36 (-1.10%)
AMZN   141.91 (-1.98%)
TSLA   906.57 (-1.43%)
NVDA   183.44 (-2.83%)
NIO   20.40 (-2.44%)
BABA   91.17 (-1.60%)
AMD   97.61 (-2.58%)
MU   61.33 (-3.96%)
T   18.42 (-0.81%)
CGC   4.23 (+11.90%)
F   16.17 (-1.58%)
GE   79.98 (-1.34%)
DIS   123.86 (-0.88%)
AMC   23.67 (-4.59%)
PYPL   100.19 (-1.85%)
PFE   49.50 (-0.72%)
NFLX   240.70 (-2.03%)
S&P 500   4,267.21 (-0.88%)
DOW   33,931.85 (-0.64%)
QQQ   328.60 (-1.11%)
AAPL   173.88 (+0.49%)
MSFT   291.65 (-0.36%)
META   175.90 (-1.99%)
GOOGL   120.36 (-1.10%)
AMZN   141.91 (-1.98%)
TSLA   906.57 (-1.43%)
NVDA   183.44 (-2.83%)
NIO   20.40 (-2.44%)
BABA   91.17 (-1.60%)
AMD   97.61 (-2.58%)
MU   61.33 (-3.96%)
T   18.42 (-0.81%)
CGC   4.23 (+11.90%)
F   16.17 (-1.58%)
GE   79.98 (-1.34%)
DIS   123.86 (-0.88%)
AMC   23.67 (-4.59%)
PYPL   100.19 (-1.85%)
PFE   49.50 (-0.72%)
NFLX   240.70 (-2.03%)
NASDAQ:BYSI

BeyondSpring - BYSI Stock Forecast, Price & News

$1.73
+0.09 (+5.49%)
(As of 08/17/2022 10:19 AM ET)
Add
Compare
Today's Range
$1.72
$1.74
50-Day Range
$1.32
$2.16
52-Week Range
$1.13
$33.00
Volume
139 shs
Average Volume
167,769 shs
Market Capitalization
$67.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

BeyondSpring MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
1,729.3% Upside
$30.00 Price Target
Short Interest
Bearish
14.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of BeyondSpring in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.80) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

977th out of 1,122 stocks

Pharmaceutical Preparations Industry

486th out of 551 stocks

BYSI stock logo

About BeyondSpring (NASDAQ:BYSI) Stock

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

BeyondSpring Stock Up 0.6 %

Shares of BYSI Stock opened at $1.64 on Wednesday. BeyondSpring has a 52-week low of $1.13 and a 52-week high of $33.00. The stock has a market cap of $63.85 million, a PE ratio of -1.00 and a beta of 1.04. The business has a 50-day simple moving average of $1.52 and a 200-day simple moving average of $1.89.

Receive BYSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter.

BYSI Stock News Headlines

BeyondSpring Files 2021 Annual Report on Form 20-F
See More Headlines
Receive BYSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter.

BYSI Company Calendar

Last Earnings
12/29/2021
Today
8/17/2022
Next Earnings (Estimated)
9/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BYSI
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.00
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,634.1%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-64,180,000.00
Net Margins
-4,750.48%
Pretax Margin
-4,784.46%

Debt

Sales & Book Value

Annual Sales
$1.35 million
Book Value
$0.54 per share

Miscellaneous

Free Float
N/A
Market Cap
$67.35 million
Optionable
Not Optionable
Beta
1.04














BYSI Stock - Frequently Asked Questions

Should I buy or sell BeyondSpring stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BYSI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BYSI, but not buy additional shares or sell existing shares.
View BYSI analyst ratings
or view top-rated stocks.

What is BeyondSpring's stock price forecast for 2022?

6 analysts have issued twelve-month price objectives for BeyondSpring's stock. Their BYSI share price forecasts range from $5.00 to $65.00. On average, they expect the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 1,729.3% from the stock's current price.
View analysts price targets for BYSI
or view top-rated stocks among Wall Street analysts.

How have BYSI shares performed in 2022?

BeyondSpring's stock was trading at $4.53 at the beginning of 2022. Since then, BYSI shares have decreased by 63.8% and is now trading at $1.64.
View the best growth stocks for 2022 here
.

When is BeyondSpring's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, September 9th 2022.
View our BYSI earnings forecast
.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings results on Wednesday, December, 29th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.11. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.34 million. BeyondSpring had a negative net margin of 4,750.48% and a negative trailing twelve-month return on equity of 144.52%.

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

When did BeyondSpring IPO?

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

Who are BeyondSpring's major shareholders?

BeyondSpring's stock is owned by many different retail and institutional investors. Top institutional investors include Millennium Management LLC (1.78%), Renaissance Technologies LLC (0.94%), BNP Paribas Arbitrage SA (0.64%), Hennion & Walsh Asset Management Inc. (0.24%), State Street Corp (0.24%) and Citadel Advisors LLC (0.00%).

How do I buy shares of BeyondSpring?

Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $1.64.

How much money does BeyondSpring make?

BeyondSpring (NASDAQ:BYSI) has a market capitalization of $63.85 million and generates $1.35 million in revenue each year. The company earns $-64,180,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The official website for the company is www.beyondspringpharma.com. The company can be reached via phone at (646) 305-6387, via email at general@beyondspringpharma.com, or via fax at 1-646-882-4228.

This page (NASDAQ:BYSI) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.